Overview

Churg-Strauss syndrome is a disorder marked by blood vessel inflammation. This inflammation can restrict blood flow to organs and tissues, sometimes permanently damaging them. This condition is also known as eosinophilic granulomatosis with polyangiitis (EGPA).

Adult-onset asthma is the most common sign of Churg-Strauss syndrome. The disorder can also cause other problems, such as nasal allergies, sinus problems, rash, gastrointestinal bleeding, and pain and numbness in your hands and feet.

Churg-Strauss syndrome is rare and has no cure. Symptoms can usually be controlled with steroids and other powerful immunosuppressant drugs.

Products & Services
A Book: Future Care

Symptoms

When to see a doctor

Request an appointment


Complications

Blood clots are a dangerous complication of atrial fibrillation (AFib). Blood clots can lead to stroke.
The risk of stroke from AFib increases as you grow older. Other health conditions also may increase the risk of a stroke due to AFib. These conditions include:
  • High blood pressure.
  • Diabetes.
  • Heart failure.
  • Some types of heart valve disease.
Blood thinners are commonly prescribed to prevent blood clots and strokes in people with atrial fibrillation.

Prevention

Healthy lifestyle choices can reduce the risk of heart disease and may prevent atrial fibrillation (AFib). Here are some basic heart-healthy tips:
  • Control high blood pressure, high cholesterol and diabetes.
  • Don't smoke or use tobacco.
  • Eat a diet that's low in salt and saturated fat.
  • Exercise at least 30 minutes a day on most days of the week unless your health care team says not to.
  • Get good sleep. Adults should aim for 7 to 9 hours daily.
  • Maintain a healthy weight.
  • Reduce and manage stress.


Print

Living with atrial fibrillation?

Connect with others like you for support and answers to your questions in the Heart Rhythm Conditions support group on Freedmans Health Clinic Connect, a patient community.

Heart Rhythm Conditions Discussions

See more discussions

Comments are closed for this post.